AAV-FIX Gene Therapy - ASC Therapeutics [54869]
Alternative Names: Adeno associated viral vector factor IX gene therapy - ASC Therapeutics; Adeno-associated viral vector haemophilia B gene therapy - ASC TherapeuticsLatest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator ASC Therapeutics
- Class Blood coagulation factors; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia B
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Haemophilia-B in USA (Parenteral)
- 25 Jun 2019 Preclinical trials in Haemophilia B in USA (Parenteral) (ASC Therapeutics pipeline June 2019)